Tenaya Therapeutics (TNYA) Liabilities and Shareholders Equity (2020 - 2026)

Tenaya Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $135.1 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 6.17% year-over-year to $135.1 million; the TTM figure through Mar 2026 stood at $509.1 million (down 10.31% YoY), while the FY2025 annual figure was $146.9 million, up 22.5% from the prior year.
• Liabilities and Shareholders Equity was $135.1 million for Q1 2026 at Tenaya Therapeutics, down from $146.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $281.5 million in Q1 2022 to a low of $105.0 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $184.4 million across 5 years, with a median of $170.5 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity surged 63.12% in 2022, then plunged 38.87% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $278.9 million in 2022, then sank by 38.87% to $170.5 million in 2023, then decreased by 29.66% to $119.9 million in 2024, then rose by 22.5% to $146.9 million in 2025, then retreated by 8.07% to $135.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $135.1 million (Q1 2026), $146.9 million (Q4 2025), and $105.0 million (Q3 2025), per Business Quant data.